Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus PREDNICEN M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus PREDNICEN M.
DEXASPORIN vs PREDNICEN-M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Prednicen-M is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also induces lipocortin synthesis, which inhibits arachidonic acid release.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Oral, 5-60 mg/day divided every 6-12 hours, adjusted based on disease severity and response.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
2-3 hours (prednisone); terminal half-life of prednisolone is 2-4 hours in normal renal function, prolonged to 3-4 hours in renal impairment, and may be extended in hepatic impairment.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal: ~80% as metabolites and unchanged drug (primarily as 17-ketosteroids and glucuronide conjugates); fecal: <5%; biliary: minor.
Category C
Category C
Corticosteroid/Antibiotic Combination
Ophthalmic Corticosteroid/Antibiotic Combination